Avenues to Early and Better Regulatory Access was presented at the 2025 Mayer Brown Utah Life Sciences Summit on November 12, 2025, in Salt Lake City. Presented by BioUtah, Chris Phillips, RAPS, served as moderator with panelists including Kai Kadoich, FDA / CDRH / TAP Program, TAP Advisor; Kelli Oborn, BSI Group, Senior Technical Specialist; […]
How AI is Driving Trends in Life Sciences was presented at the 2026 Mayer Brown Utah Life Sciences Summit on November 12, 2025, in Salt Lake City. Moderated by Ryan Hogan, Pace Johnson Law Group, CEO, panelists included Kelli Oborn, BSI Group, Senior Technical Specialist; Heather Murphy, BSI; Brynn Stanley, Gardner Law, Associate Attorney; and […]
Early Experience with an Evolving FDA and HHS was presented at the 2025 Utah Life Sciences Summit on November 12, 2025 in Salt Lake City. Moderated by Seth Olson, Kirton McConkie, attorney, panelists included Peter Marks, MD/PhD, Eli Lilly, Sr. VP of Molecule Discovery & Head of Infectious Disease, Eli Lilly; Former Director, Center for […]
Mapping Utah’s Life Sciences Developments was presented at the 2025 Utah Life Sciences Summit in Salt Lake City on November 12, 2025. Moderated by Chris Kirk, Colliers, Managing Director, panelists included Michael Ambre, POMSLA, Executive Director of The Point of The Mountain State Land Authority; Ben Hart, Utah Inland Port Authority, Executive Director; J. Steven […]
Making Social Media Work for Your Company was presented by Nathan Gwilliam on November 12, 2025 at the 2025 Utah Life Sciences in Salt Lake City. Social media platforms can provide life sciences companies with an impactful tool for marketing, sharing research, patient outreach, professional networking, and product education – all amid an intricate regulatory […]
The Fundamentals of Reimbursement in US Healthcare by Stryker’s Amanda Morrison was presented on November 12, 2025, at the Mayer Brown 2025 Utah Life Sciences Summit in Salt Lake City. Reimbursement in the U.S. healthcare system is the payment providers receive for medical services and products, primarily through government payers like Medicare, Medicaid, the VA, […]
Once a medical device has been approved by FDA and received a reimbursement code, companies turn their attention to selling their products, only to learn that 80% of hospitals buy their products through contracts negotiated with Group Purchasing Organizations. Todd Ebert recently retired as the head of the National Healthcare Supply Chain Association. He possesses […]
This panel explored how artificial intelligence is transforming drug discovery and development, from accelerating target identification to optimizing clinical trial design. Industry leaders and innovators will discuss how AI-driven insights are reshaping the future of precision medicine, speed, and success in bringing new therapies to patients. Moderator: David Bearss, Ph.D., Halia Therapeutics, President & Chief […]
The National Security Commission on Emerging Biotechnology (NSCEB) was established by Congress in 2022 as part of the National Defense Act. The NSCEB was tasked with conducting a thorough review of how advancements in emerging biotechnology and related technologies will shape current and future activities of the Department of Defense. This fireside chat between Michelle […]
As the former director of the Center for Biologics Evaluation and Research at the FDA, Peter Marks, MD, PhD, discusses new drug and biologic developments that also gave him insight into what is coming in the future. […]